Previous 10 | Next 10 |
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Nektar Therapeutics (NKTR) is expected to report $-0.18 for Q3 2023
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial resu...
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress PR Newswire – Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rap...
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy PR Newswire – Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be...
2023-09-27 12:47:12 ET More on Nektar Therapeutics Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript Data Errors Could Give Nektar Therapeutics A New Lease On Life Nektar reportedly sues Lilly for bungling clinical data on dermo drug Seeking Alpha...
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer PR Newswire SAN FRANCISCO , Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeu...
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PR Newswire New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study ...
2023-09-11 14:22:11 ET Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to tradit...
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th PR Newswire SAN FRANCISCO , Sept. 6, 2023 /...
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 PR Newswire – NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic ...
Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare C...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...